Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A bronchial gene signature specific for severe COPD that is retained in the nose.

Autor: van Nijnatten J; University of Groningen, University Medical Center Groningen, Department of Pathology and Medical Biology, Groningen, the Netherlands.; University of Groningen University Medical Center Groningen, Groningen Research Institute for Asthma and COPD, Groningen, the Netherlands.; University of Technology Sydney, Respiratory Bioinformatics and Molecular Biology, Sydney, NSW, Australia., Faiz A; University of Groningen University Medical Center Groningen, Groningen Research Institute for Asthma and COPD, Groningen, the Netherlands.; University of Technology Sydney, Respiratory Bioinformatics and Molecular Biology, Sydney, NSW, Australia.; University of Groningen University Medical Center Groningen, Department of Pulmonary Diseases, Groningen, the Netherlands., Timens W; University of Groningen, University Medical Center Groningen, Department of Pathology and Medical Biology, Groningen, the Netherlands.; University of Groningen University Medical Center Groningen, Groningen Research Institute for Asthma and COPD, Groningen, the Netherlands., Guryev V; University of Groningen University Medical Center Groningen, European Research Institute for the Biology of Ageing, Groningen, the Netherlands., Slebos DJ; University of Groningen University Medical Center Groningen, Groningen Research Institute for Asthma and COPD, Groningen, the Netherlands.; University of Groningen University Medical Center Groningen, Department of Pulmonary Diseases, Groningen, the Netherlands., Klooster K; University of Groningen University Medical Center Groningen, Groningen Research Institute for Asthma and COPD, Groningen, the Netherlands.; University of Groningen University Medical Center Groningen, Department of Pulmonary Diseases, Groningen, the Netherlands., Hartman JE; University of Groningen University Medical Center Groningen, Groningen Research Institute for Asthma and COPD, Groningen, the Netherlands.; University of Groningen University Medical Center Groningen, Department of Pulmonary Diseases, Groningen, the Netherlands., Kole T; University of Groningen University Medical Center Groningen, Groningen Research Institute for Asthma and COPD, Groningen, the Netherlands.; University of Groningen University Medical Center Groningen, Department of Pulmonary Diseases, Groningen, the Netherlands., Choy DF; Genentech Inc., South San Francisco, CA, USA., Chakrabarti A; Genentech Inc., South San Francisco, CA, USA., Grimbaldeston M; Genentech Inc., South San Francisco, CA, USA., Rosenberger CM; Genentech Inc., South San Francisco, CA, USA., Kerstjens H; University of Groningen University Medical Center Groningen, Department of Pulmonary Diseases, Groningen, the Netherlands., Brandsma CA; University of Groningen, University Medical Center Groningen, Department of Pathology and Medical Biology, Groningen, the Netherlands.; University of Groningen University Medical Center Groningen, Groningen Research Institute for Asthma and COPD, Groningen, the Netherlands.; These authors contributed equally., van den Berge M; University of Groningen University Medical Center Groningen, Groningen Research Institute for Asthma and COPD, Groningen, the Netherlands.; University of Groningen University Medical Center Groningen, Department of Pulmonary Diseases, Groningen, the Netherlands.; These authors contributed equally.

Publikováno v: ERJ open research [ERJ Open Res] 2023 Nov 27; Vol. 9 (6). Date of Electronic Publication: 2023 Nov 27 (Print Publication: 2023).

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Development of an ultra-sensitive human IL-33 biomarker assay for age-related macular degeneration and asthma drug development.

Autor: Mai E; Department of Biochemical and Cellular Pharmacology, Genentech Inc., South San Francisco, CA, USA., Chan J; Department of Biochemical and Cellular Pharmacology, Genentech Inc., South San Francisco, CA, USA., Goon L; Department of Biochemical and Cellular Pharmacology, Genentech Inc., South San Francisco, CA, USA.; Department of Biology and Compound Repository, Exelixis, Alameda, CA, USA., Ego BK; Department of Biochemical and Cellular Pharmacology, Genentech Inc., South San Francisco, CA, USA.; Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA., Bevers J; Department of Antibody Engineering, Genentech Inc., South San Francisco, CA, USA., Wong T; Department of Structural Biology, Genentech Inc., South San Francisco, CA, USA., Wong M; Department of Structural Biology, Genentech Inc., South San Francisco, CA, USA., Corpuz R; Department of Structural Biology, Genentech Inc., South San Francisco, CA, USA., Xi H; Department of Antibody Engineering, Genentech Inc., South San Francisco, CA, USA.; Department of Immunology, Genentech Inc., South San Francisco, CA, USA., Wu J; Department of Antibody Engineering, Genentech Inc., South San Francisco, CA, USA., Schneider K; Department of Antibody Engineering, Genentech Inc., South San Francisco, CA, USA., Seshasayee D; Department of Antibody Engineering, Genentech Inc., South San Francisco, CA, USA., Grimbaldeston M; Department of OMNI-Biomarker Development, Genentech Inc., South San Francisco, CA, USA., Nakamura G; Department of Antibody Engineering, Genentech Inc., South San Francisco, CA, USA., Indjeian VB; Department of OMNI-Biomarker Development, Genentech Inc., South San Francisco, CA, USA., van Lookeren Campagne M; Department of Immunology, Genentech Inc., South San Francisco, CA, USA.; Department of Inflammation and Oncology, Amgen Research, Amgen Inc., South San Francisco, CA, USA., Loyet KM; Department of Biochemical and Cellular Pharmacology, Genentech Inc., South San Francisco, CA, USA., Comps-Agrar L; Department of Biochemical and Cellular Pharmacology, Genentech Inc., South San Francisco, CA, USA. compsagl@gene.com.

Publikováno v: Journal of translational medicine [J Transl Med] 2021 Dec 20; Vol. 19 (1), pp. 517. Date of Electronic Publication: 2021 Dec 20.

High serum granulocyte-colony stimulating factor characterises neutrophilic COPD exacerbations associated with dysbiosis.

Autor: Chakrabarti A; Biomarker Discovery OMNI, Genentech Inc., South San Francisco, CA, USA., Mar JS; Biomarker Discovery OMNI, Genentech Inc., South San Francisco, CA, USA., Choy DF; Biomarker Discovery OMNI, Genentech Inc., South San Francisco, CA, USA., Cao Y; Bioinformatics, Genentech Inc., South San Francisco, CA, USA., Rathore N; Biomarker Discovery OMNI, Genentech Inc., South San Francisco, CA, USA., Yang X; Biostatistics, Genentech Inc., South San Francisco, CA, USA., Tew GW; OMNI Biomarker Development, Genentech Inc., South San Francisco, CA, USA., Li O; OMNI Biomarker Development, Genentech Inc., South San Francisco, CA, USA., Woodruff PG; Dept of Medicine, UCSF, San Francisco, CA, USA., Brightling CE; Dept of Respiratory Sciences, University of Leicester, Leicester, UK., Grimbaldeston M; OMNI Biomarker Development, Genentech Inc., South San Francisco, CA, USA., Christenson SA; Dept of Medicine, UCSF, San Francisco, CA, USA., Bafadhel M; Nuffield Dept of Medicine, University of Oxford, Oxford, UK., Rosenberger CM; Biomarker Discovery OMNI, Genentech Inc., South San Francisco, CA, USA.

Publikováno v: ERJ open research [ERJ Open Res] 2021 Aug 02; Vol. 7 (3). Date of Electronic Publication: 2021 Aug 02 (Print Publication: 2021).